Alan T. Yeo

发表

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2012, Science Translational Medicine.

Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression

V. Boussiotis, H. Varma, A. Charest, 2022, Nature immunology.

The complex role of tumor-infiltrating macrophages

V. Boussiotis, A. Charest, Alan T. Yeo, 2022, Nature Immunology.

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma

A. Charest, Alan T. Yeo, Alan T Yeo, 2017, Journal of cellular biochemistry.

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

A. Letai, Kwok-Kin Wong, M. Mino‐Kenudson, 2014, Cancer research.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

S. Ramaswamy, M. Rivera, T. Jacks, 2015, Proceedings of the National Academy of Sciences.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine

S. Gygi, J. Sarkaria, K. Ligon, 2018, Nature Communications.

CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein

S. Miyamoto, T. Gilmore, Alan T. Yeo, 2018, bioRxiv.

Therapeutics , Targets , and Chemical Biology Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Ef fi cacy of Combined MEK and PI 3 K Inhibitors for KRAS-Mutant Lung Cancers

A. Letai, Kwok-Kin Wong, M. Mino‐Kenudson, 2014 .